V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20139972 | 20175753 | null | null | Palliative (P) | null | 2021-04-20 | ECF | 02 | Y | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101249641 |
| 20141651 | 20175754 | 1.71 | 78.15 | Curative (C) | 2017-06-09 | 2017-06-09 | ECarboX | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 100425644 |
| 20141745 | 20175755 | 1.8 | 65.4 | Palliative (P) | 2019-12-11 | 2019-12-17 | DARATUMUMAB | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101465889 |
| 20142578 | 20175756 | 1.53 | 50.5 | null | 2017-11-15 | 2019-04-14 | GEFITINIB | 02 | null | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 100943522 |
| 20142915 | 20175757 | null | null | null | 2021-06-01 | 2022-02-19 | COSMIC TRIAL | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100097838 |
| 20143244 | 20175758 | 1.81 | 61.8 | Curative (C) | 2019-05-31 | 2019-06-21 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100190619 |
| 20143370 | 20175759 | null | 74.15 | null | 2017-01-27 | 2017-01-29 | INTERAACT trial | 02 | N | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 100028118 |
| 20143492 | 20175760 | 1.56 | 59.8 | Palliative (P) | 2020-07-28 | 2020-08-09 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | ECARBOX | 100834785 |
| 20143702 | 20175761 | 1.46 | 79 | Curative (C) | 2017-11-28 | 2018-03-18 | ACTICCA-1 Trial | 02 | null | DARATUMUMAB | 100482860 |
| 20143988 | 20175762 | 1.56 | 0 | null | 2019-10-29 | 2019-11-03 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 02 | null | SCOPE2 TRIAL | 101187221 |
| 20144687 | 20175763 | 1.77 | 53.9 | Palliative (P) | 2018-02-15 | 2018-03-08 | Etoposide IV | 02 | null | EPIRUBICIN | 100262936 |
| 20144867 | 20175764 | 1.79 | 66.2 | 03 | 2019-11-09 | 2019-11-12 | LORLATINIB | 02 | N | CAPECITABINE + DOCETAXEL | 100413733 |
| 20147170 | 20175765 | 1.65 | null | Palliative (P) | 2020-04-10 | 2020-04-23 | Ifosfamide | 02 | N | IBRUTINIB | 101789225 |
| 20147403 | 20175766 | 1.81 | 70 | Palliative (P) | 2019-07-07 | 2019-09-02 | EC | 02 | N | GEMCITABINE + OXALIPLATIN | 100772465 |
| 20148182 | 20175768 | 0 | 78.3 | Palliative (P) | 2018-02-20 | 2019-03-21 | PHITT D Carboplatin / doxorubicin . | 02 | N | TEMOZOLOMIDE | 101627462 |
| 20148558 | 20175769 | 1.81 | 93.8 | Curative (C) | 2020-08-06 | 2020-08-08 | ECarboF | 02 | N | DARATUMUMAB | 101213518 |
| 20149423 | 20175771 | 1.77 | 85.9 | 03 | 2021-08-11 | 2021-08-24 | Bevacizumab + Irinotecan + MdG | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 101183253 |
| 20150859 | 20175772 | 1.77 | 11.9 | Palliative (P) | 2017-09-06 | 2021-08-14 | BORTEZOMIB + THALIDOMIDE | 02 | N | CARBOPLATIN + VINORELBINE | 101533733 |
| 20151823 | 20175773 | 1.75 | 56.5 | Curative (C) | 2022-04-25 | 2022-05-03 | GO2 TRIAL | 02 | N | NAB-PACLITAXEL | 100679599 |
| 20152042 | 20175774 | 1.77 | 81.2 | null | 2018-09-22 | 2018-10-12 | COSMIC TRIAL | 02 | N | TEMOZOLOMIDE | 100555245 |
| 20152086 | 20175775 | 1.83 | 77 | Palliative (P) | 2021-09-03 | 2021-09-03 | Carboplatin + Vinorelbine Oral | 02 | null | RITUXIMAB | 100729830 |
| 20153102 | 20175776 | 1.74 | 68 | null | 2018-03-29 | 2018-03-29 | Docetaxel + Nintedanib | 02 | N | MELPHALAN | 100467017 |
| 20153571 | 20175777 | null | null | Curative (C) | 2022-02-25 | 2022-03-11 | Capecitabine + Streptozocin | 02 | N | FOCUS4 TRIAL | 101299683 |
| 20153599 | 20175778 | 1.55 | 87.4 | Palliative (P) | 2016-10-03 | 2016-10-12 | ARISTOTLE TRIAL | 02 | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 101454725 |
| 20154024 | 20175779 | 1.75 | 83.8 | Palliative (P) | 2020-02-13 | 2020-04-09 | POMALIDOMIDE | 02 | N | CAPECITABINE + STREPTOZOCIN | 101388079 |
| 20154786 | 20175782 | 1.81 | 53.4 | Adjuvant (A) | 2019-04-10 | 2019-05-25 | Hepatoblastoma SR Cisplatin | 02 | N | RUCAPARIB | 100122535 |
| 20155475 | 20175783 | 1.56 | 80.8 | Curative (C) | 2021-04-18 | 2021-07-04 | Pertuzumab (Loading) | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 101204404 |
| 20155759 | 20175785 | 1.65 | 66.2 | Palliative (P) | 2020-02-22 | 2020-04-16 | SCOPE 2 TRIAL | 02 | N | IRINOTECAN + RALTITREXED | 101793421 |
| 20157177 | 20175788 | 1.79 | 67 | Palliative (P) | 2021-11-09 | 2021-12-05 | SCOPE 2 TRIAL | 02 | N | CISPLATIN + DOCETAXEL | 101243634 |
| 20157247 | 20175789 | 1.75 | 62.6 | Palliative (P) | 2021-04-08 | 2021-06-01 | Cisplatin + Radiotherapy + CISPLATIN | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 101484743 |
| 20158965 | 20175791 | 1.52 | 47 | Palliative (P) | 2018-09-03 | 2018-09-09 | Hydroxycarbamide | 02 | N | DARATUMUMAB | 101443493 |
| 20159094 | 20175792 | 1.57 | 70 | Palliative (P) | 2020-09-08 | 2020-09-24 | CARBOPLATIN + CETUXIMAB + FU | 02 | N | MITOMYCIN | 101121232 |
| 20159217 | 20175793 | 1.71 | 37.9 | Palliative (P) | 2022-01-15 | 2022-02-14 | CAPECITABINE + MITOMYCIN + RT | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100609557 |
| 20159318 | 20175794 | 1.51 | 109.4 | null | 2017-01-17 | 2017-02-10 | Carboplatin + Liposomal Doxorubicin | 02 | N | COSMIC TRIAL | 101398261 |
| 20159362 | 20175795 | 1.75 | 93.9 | Palliative (P) | 2021-01-16 | 2021-02-05 | Etoposide + Ifosfamide (5 days) | 02 | null | IBRUTINIB | 101603763 |
| 20159370 | 20175796 | 1.87 | 67.4 | null | 2020-12-11 | 2021-01-16 | ECF | 02 | null | RITUXIMAB | 101429125 |
| 20161556 | 20175798 | 1.71 | 0 | null | 2018-03-31 | 2018-04-09 | AFATINIB | 02 | null | HYDROXYCARBAMIDE | 101182578 |
| 20163011 | 20175800 | 1.75 | 79.2 | Adjuvant (A) | 2019-02-24 | 2019-08-22 | DARATUMUMAB | 02 | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 100465565 |
| 20164336 | 20175801 | 1.69 | 80.9 | null | 2018-09-09 | 2018-11-12 | AML17 TRIAL | 02 | N | ETOPOSIDE | 101712263 |
| 20164782 | 20175802 | 1.92 | 95 | Palliative (P) | 2020-04-29 | 2020-05-10 | CT7001 | 2 | null | BALLAD TRIAL | 100187380 |
| 20167598 | 20175803 | 1.82 | 66.85 | null | 2022-01-12 | 2022-03-02 | null | 02 | N | IPILIMUMAB + NIVOLUMAB | 100419704 |
| 20168615 | 20175804 | 1.84 | 87 | null | 2017-09-17 | 2017-09-17 | INTERAACT trial | 02 | null | CAPECITABINE + STREPTOZOCIN | 101279647 |
| 20169180 | 20175806 | null | null | Palliative (P) | 2016-05-08 | 2018-01-28 | Azacitidine | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100813839 |
| 20171355 | 20175808 | 1.58 | 45.9 | Palliative (P) | 2018-05-31 | 2018-06-01 | HEP HR Hepatoblastoma gde carbo dox | 02 | N | CISPLATIN + FLUOROURACIL + RT | 100547999 |
| 20171611 | 20175809 | 1.77 | 67 | Palliative (P) | 2017-10-01 | 2017-10-28 | FCarboSt | 02 | Y | ESPAC TRIAL | 100691231 |
| 20171685 | 20175810 | 1.84 | 55.8 | Palliative (P) | 2022-03-26 | 2022-04-02 | Cape+Cetuximab+Oxalip (2 wk) Maint | 02 | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100753451 |
| 20172887 | 20175812 | 1.82 | 97 | Palliative (P) | 2021-10-02 | 2021-10-22 | CAV | 02 | null | CAPECITABINE + CETUXIMAB + OXALIPLATIN | 101667430 |
| 20173337 | 20175813 | null | 94 | null | 2018-12-09 | 2018-12-14 | Pemetrexed | 02 | N | TACE-3 TRIAL | 100025739 |
| 20175290 | 20175814 | 1.6 | 80.5 | Curative (C) | 2019-07-15 | 2019-07-24 | Cisplatin + Fluorouracil + Streptozocin | 02 | N | IPILIMUMAB + NIVOLUMAB | 101297314 |
| 20177203 | 20175816 | 1.6 | 105 | null | 2020-09-27 | 2020-10-11 | Venetoclax | 02 | null | CISPLATIN + PEMETREXED | 100570393 |